New industry analyses project continued growth in the North America synovial sarcoma treatment market, with a predicted compound annual growth rate (CAGR) of 4.2% from 2026 to 2033. The report reflects increasing momentum in rare cancer research, including advances in targeted therapy, immunotherapy, and precision medicine for synovial sarcoma. What’s Driving Growth in Synovial Sarcoma […]
Rare Disease Drug Development and Synovial Sarcoma: Why Funding Still Falls Short
A recent BioSpace article highlights a critical challenge in rare disease drug development: many promising therapies are not limited by science, but by financial viability. As Kristen Hege, former SVP at Bristol Myers Squibb, explains:“Right now, as a rule of thumb, if your product isn’t going to bring in a billion dollars a year, it’s […]


